ClinicalTrials.gg
CompletedNCT06734494APPASUpdated Dec 16, 2024

Retrospective Comparison Between AirSeal® and Standard Insufflation in Appendicular Peritonitis

An observational study in Peritonitis; Acute, Acute Appendicitis and Postoperative Pain, sponsored by Destinval Christelle. Completed at 1 site in France. Open to participants aged 4 Years to 17 Years. Per ClinicalTrials.gov, last updated 2024-12-16.

Sponsored by Destinval Christelle · Observational

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
100
Ages
4 Years to 17 Years
Sex
All
01

Study summary

The AirSeal System Valve-less Trocar is known to decrease postoperative pain, consumption of analgesics, operating time, and length of stay in adults during robotic and laparoscopic procedures. The investigators would like to know if these allegations also apply to children.

Read the detailed description

From January the 1st 2022 to December the 31st 2022, 100 children aged under 18 years old had an appendicular peritonitis treated by laparoscopic appendectomy. The pediatric surgeons either used the AirSeal System Valve-less Trocar or the standard insufflation. On one hand, only the surgeon, the anesthetist and the nurses of the operating room knew which type of insufflation was used. On the other hand, the patient, his parents and the nurses in the pediatric department did not know which type of insufflation was used. The participants were divided in two groups: the Airseal group (A) and the standard group (S). In each group, the investigators studied and compared the postoperative pain, the consumption of analgesics, the operating time, and the length of stay for each participant.

02

Conditions studied

  • Peritonitis; Acute
  • Acute Appendicitis
  • Postoperative Pain
  • Laparoscopy

Keywords

  • Valveless Trocar
  • Low-pressure Insufflation
  • Standard insufflation
  • Laparoscopic Appendectomy
  • Appendicular Peritonitis
  • Retrospective Study
03

In context

Peritonitis

167 studies on the registry are indexed under Peritonitis; 23 are open to participants now.

This study's enrollment of 100 is below the median of 137 across 55 observational studies indexed under Peritonitis.

Browse Peritonitis studies →

Lead sponsor

Destinval Christelle is the lead sponsor of 3 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
4 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients aged between 4 and 17 years old who underwent laparoscopic appendectomy for appendicular peritonitis using the Airseal® or a Standard Insufflation, from 2022/01/1st to 2022/12/31st.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Children aged between 4 and 17 years old
  • Who underwent laparoscopic appendectomy for appendicular peritonitis
  • Between 2022/06/1st and 2022/12/31st

Exclusion criteria

Exclusion Criteria:

  • Children younger than 4 years old or older than 18 years old
  • Who did not have appendicular peritonitis
  • Between 2022/01/1st and 2022/12/31st
05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
100 participants (actual)
Patient registry
No

Groups and cohorts

  • Airseal group (A)

    Patients who underwent a laparoscopic appendectomy using Airseal

    Device: Laparoscopic appendectomy Laparoscopic appendectomy with Airseal or with standard insufflation

  • Standard group (S)

    Patients who underwent a laparoscopic appendectomy using standard insufflation

    Device: Laparoscopic appendectomy Laparoscopic appendectomy with Airseal or with standard insufflation

Interventions

  • DeviceLaparoscopic appendectomy Laparoscopic appendectomy with Airseal or with standard insufflation

    Airseal is a constant and low-pressure insufflation device. Standard insufflation is a variable pressure insufflation device.

06

What researchers measure

Primary outcomes

  1. Consumption of analgesics

    Number of medications taken during hospitalization

    Time frame: From the end of surgery to the discharge home, up to 20 days

Secondary outcomes

  1. Length of stay

    Length of stay

    Time frame: From the admission to the discharge home, up to 20 days

  2. Operating Time

    Time to operate the patients

    Time frame: From beginning to end of surgery

  3. Mean Digital Pain Scale

    Digital Pain Scale: minimum is 0 out of 10 (which means no pain) and maximum is 10 out of 10 (which means very painful). Higher scores mean worse outcomes.

    Time frame: Immediately after surgery until discharge home, up to 20 days

07

Study locations

1 site
  • University Hospital, Clermont-Ferrand
    Clermont-Ferrand, Auvergne 63003, France
08

References and documents

Publications

  • Hua J, Gong J, Yao L, Zhou B, Song Z. Low-pressure versus standard-pressure pneumoperitoneum for laparoscopic cholecystectomy: a systematic review and meta-analysis. Am J Surg. 2014 Jul;208(1):143-50. doi: 10.1016/j.amjsurg.2013.09.027. Epub 2014 Jan 16. PubMed 24503370 ↗
  • Rebuck DA, Zhao LC, Helfand BT, Casey JT, Navai N, Perry KT, Nadler RB. Simple modifications in operating room processes to reduce the times and costs associated with robot-assisted laparoscopic radical prostatectomy. J Endourol. 2011 Jun;25(6):955-60. doi: 10.1089/end.2010.0534. Epub 2011 Apr 2. PubMed 21457071 ↗
  • de'Angelis N, Petrucciani N, Giannandrea G, Brunetti F. The protocol of low-impact laparoscopic cholecystectomy: the combination of mini-laparoscopy and low-pressure pneumoperitoneum. Updates Surg. 2018 Dec;70(4):553-556. doi: 10.1007/s13304-018-0591-8. Epub 2018 Aug 29. PubMed 30159821 ↗

Individual participant data

Plan to share: No — In the name of anonymization we won't share individual participant data

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 16, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06734494
Lead sponsor
Destinval Christelle
Responsible party
Destinval Christelle (Dr., University Hospital, Clermont-Ferrand) — Sponsor-investigator
First posted
Dec 16, 2024
Start date
Jan 1, 2022
Primary completion
Dec 31, 2022
Completion
Jan 1, 2023
Last update
Dec 16, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion